SLCO1B1 gene-based clinical decision support reduces statin-associated muscle symptoms risk with simvastatin

Papers of special note have been highlighted as: • of interest

References

• 1. Vasan RS, Enserro DM, Xanthakis V, Beiser AS, Seshadri S. Temporal trends in the remaining lifetime risk of cardiovascular disease among middle-aged adults across 6 decades: the Framingham Study. Circulation 145(17), 1324–1338 (2022).
  MedlineGoogle Scholar
• 2. Chou R, Cantor A, Dana T et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: A Systematic Review for the U.S. Preventive Services Task Force. Pacific Northwest Evidence-Based Practice Center, OR, USA (2022).
  Google Scholar
• 3. Arnett DK, Blumenthal RS, Albert MA et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 74(10), 1376–1414 (2019).
  MedlineGoogle Scholar
• 4. Voora D, Shah SH, Spasojevic I et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol. 54(17), 1609–1616 (2009).
  Medline CASGoogle Scholar
• 5. Gislason GH, Rasmussen JN, Abildstrøm SZ et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur. Heart J. 27(10), 1153–1158 (2006).
  Medline CASGoogle Scholar
• 6. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW, Stang MR, Semchuk WM. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can. J. Cardiol. 21(6), 485–488 (2005).
  Medline CASGoogle Scholar
• 7. Swen JJ, van der Wouden CH, Manson LE et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet 401(10374), 347–356 (2023). • Preemptive pharmacogenomic testing significantly decreased adverse effects.
  Medline CASGoogle Scholar
• 8. Petry NJ, Baye JF, Frear S et al. Progression of precision statin prescribing for reduction of statin-associated muscle symptoms. Pharmacogenomics 23(10), 585–596 (2022). • SLCO1B1 testing can help mitigate risk for developing statin-associated muscle symptoms.
  CASGoogle Scholar
• 9. Cooper-DeHoff RM, Niemi M, Ramsey LB et al. The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms. Clin. Pharmacol. Ther. 111(5), 1007–1021 (2022).
  Medline CASGoogle Scholar
• 10. Peyser B, Perry EP, Singh K et al. Effects of delivering SLCO1B1 pharmacogenetic information in randomized trial and observational settings. Circ. Genom. Precis. Med. 11(9), e002228 (2018).
  Medline CASGoogle Scholar
• 11. Kee PS, Chin PKL, Kennedy MA, Maggo SDS. Pharmacogenetics of statin-induced myotoxicity. Front. Genet. 11, 575678 (2020).
  Medline CASGoogle Scholar
• 12. Merck. ZOCOR (simvastatin) Tablets. Initial U.S. Approval: 1991 Merck Sharp & Dohme Ltd (2012).
  Google Scholar
• 13. Donnelly LA, Doney AS, Tavendale R et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with Type 2 diabetes: a go-DARTS study. Clin. Pharmacol. Ther. 89(2), 210–216 (2011).
  Medline CASGoogle Scholar
• 14. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch. Intern. Med. 165(22), 2671–2676 (2005).
  MedlineGoogle Scholar
• 15. Mendes P, Robles PG, Mathur S. Statin-induced rhabdomyolysis: a comprehensive review of case reports. Physiother. Can. 66(2), 124–132 (2014).
  MedlineGoogle Scholar
• 16. Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin. Drug Saf. 10(3), 373–387 (2011).
  Medline CASGoogle Scholar
• 17. Petry N, Baye J, Aifaoui A et al. Implementation of wide-scale pharmacogenetic testing in primary care. Pharmacogenomics 20(12), 903–913 (2019).
  Google Scholar
• 18. Shuldiner AR, Relling MV, Peterson JF et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin. Pharmacol. Ther. 94(2), 207–210 (2013).
  Medline CASGoogle Scholar
• 19. Arwood MJ, Chumnumwat S, Cavallari LH, Nutescu EA, Duarte JD. Implementing pharmacogenomics at your institution: establishment and overcoming implementation challenges. Clin. Transl. Sci. 9(5), 233–245 (2016).
  Medline CASGoogle Scholar
• 20. Hoffman JM, Flynn AJ, Juskewitch JE, Freimuth RR. Biomedical data science and informatics challenges to implementing pharmacogenomics with electronic health records. Annu. Rev. Biomed. Data Sci. 289–314 (2020).
  Google Scholar
• 21. Caraballo PJ, Sutton JA, Giri J et al. Integrating pharmacogenomics into the electronic health record by implementing genomic indicators. J. Am. Med. Inform. Assoc. 27(1), 154–158 (2020).
  MedlineGoogle Scholar
• 22. Peterson JF, Field JR, Unertl KM et al. Physician response to implementation of genotype-tailored antiplatelet therapy. Clin. Pharmacol. Ther. 100(1), 67–74 (2016).
  Medline CASGoogle Scholar
• 23. Weitzel KW, Elsey AR, Langaee TY et al. Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am. J. Med. Genet. C Semin. Med. Genet. 166c(1), 56–67 (2014).
  MedlineGoogle Scholar
• 24. Obeng AO, Scott SA, Kaszemacher T et al. Prescriber adoption of SLCO1B1 genotype-guided simvastatin clinical decision support in a clinical pharmacogenetics program. Clin. Pharmacol. Ther. 113(2), 321–327 (2023). • Providers with pharmacogenomic training were significantly more likely to accept clinical decision support for genetic guided simvastatin prescribing.
  MedlineGoogle Scholar
• 25. Petry NJ, Curtis B, Feldhege E et al. Impact of automated best practice advisories on provider response to CYP2C19 genotyping results for patients on clopidogrel. J. Pharm. Pract. 36(3), 487–493 (2023).
  MedlineGoogle Scholar
• 26. Nguyen JQ, Crews KR, Moore BT et al. Clinician adherence to pharmacogenomics prescribing recommendations in clinical decision support alerts. J. Am. Med. Inform. Assoc. 30(1), 132–138 (2022).
  MedlineGoogle Scholar
• 27. O'Donnell PH, Wadhwa N, Danahey K et al. Pharmacogenomics-based point-of-care clinical decision support significantly alters drug prescribing. Clin. Pharmacol. Ther. 102(5), 859–869 (2017).
  MedlineGoogle Scholar
• 28. Smith DM, Wake DT, Dunnenberger HM. Pharmacogenomic clinical decision support: a scoping review. Clin. Pharmacol. Ther. 113(4), 803–815 (2023).
  Medline CASGoogle Scholar
• 29. Christensen KD, Bell M, Zawatsky CLB et al. Precision population medicine in primary care: the Sanford Chip experience. Front. Genet. 12(274), 626845 (2021).
  Medline CASGoogle Scholar
• 30. Hajek C, Hutchinson AM, Galbraith LN et al. Improved provider preparedness through an 8-part genetics and genomic education program. Genet. Med. 24(1), 214–224 (2022).
  Medline CASGoogle Scholar
• 31. Larson EA, Wilke RA. Integration of genomics in primary care.. Am. J. Med. 128(11), 1251.e1251–1255 (2015).
  Google Scholar
• 32. Grundy SM, Stone NJ, Bailey AL et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation 139(25), e1082–e1143 (2019).
  MedlineGoogle Scholar
• 33. Pan W. Akaike's information criterion in generalized estimating equations. Biometrics 57(1), 120–125 (2001).
  Medline CASGoogle Scholar
• 34. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria (2017).
  Google Scholar
• 35. Roden DM, Van Driest SL, Mosley JD et al. Benefit of preemptive pharmacogenetic information on clinical outcome. Clin. Pharmacol. Ther. 103(5), 787–794 (2018).
  MedlineGoogle Scholar
• 36. Weitzel KW, Cavallari LH, Lesko LJ. Preemptive panel-based pharmacogenetic testing: the time is now. Pharm. Res. 34(8), 1551–1555 (2017).
  Medline CASGoogle Scholar
• 37. Ji Y, Skierka JM, Blommel JH et al. Preemptive pharmacogenomic testing for precision medicine: a comprehensive analysis of five actionable pharmacogenomic genes using next-generation DNA sequencing and a customized CYP2D6 genotyping cascade. J. Mol. Diagn. 18(3), 438–445 (2016).
  MedlineGoogle Scholar
• 38. Rehm HL. Evolving health care through personal genomics. Nat. Rev. Genet. 18(4), 259–267 (2017).
  Medline CASGoogle Scholar
• 39. Elroy M. Researchers and policymakers point to successes and challenges in personalized medicine. In: American Association for the Advancement of Science (AAAS). (2009). https://www.aaas.org/news/researchers-and-policymakers-point-successes-and-challenges-personalized-medicine
  Google Scholar
• 40. Link E, Parish S, Armitage J et al. SLCO1B1 variants and statin-induced myopathy – a genomewide study. N. Engl. J. Med. 359(8), 789–799 (2008).
  Medline CASGoogle Scholar
• 41. Bitzur R, Cohen H, Kamari Y, Harats D. Intolerance to statins: mechanisms and management. Diabetes Care 36(Suppl. 2), S325–S330 (2013).
  Medline CASGoogle Scholar
• 42. Sathasivam S, Lecky B. Statin induced myopathy. BMJ 337, a2286 (2008).
  MedlineGoogle Scholar
• 43. Tolley CL, Slight SP, Husband AK, Watson N, Bates DW. Improving medication-related clinical decision support. Am. J. Health Syst. Pharm. 75(4), 239–246 (2018).
  MedlineGoogle Scholar
• 44. Hinderer M, Boeker M, Wagner SA et al. Integrating clinical decision support systems for pharmacogenomic testing into clinical routine – a scoping review of designs of user-system interactions in recent system development. BMC Med. Inform. Decis. Mak. 17(1), 81 (2017).
  MedlineGoogle Scholar
• 45. Wright A, Aaron S, Seger DL, Samal L, Schiff GD, Bates DW. Reduced effectiveness of interruptive drug–drug interaction alerts after conversion to a commercial electronic health record. J. Gen. Intern. Med. 33(11), 1868–1876 (2018).
  MedlineGoogle Scholar
• 46. Voora D, Baye J, McDermaid A et al. SLCO1B1*5 allele is associated with atorvastatin discontinuation and adverse muscle symptoms in the context of routine care. Clin. Pharmacol. Ther. 111(5), 1075–1083 (2022). • Genetic variants in SLCO1B1 have been linked to patient discontinuation of atorvastatin and adverse effects.
  Medline CASGoogle Scholar
• 47. Stanek EJ, Sanders CL, Taber KA et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin. Pharmacol. Ther. 91(3), 450–458 (2012).
  Medline CASGoogle Scholar
• 48. Haga SB, Burke W, Ginsburg GS, Mills R, Agans R. Primary care physicians' knowledge of and experience with pharmacogenetic testing. Clin. Genet. 82(4), 388–394 (2012).
  Medline CASGoogle Scholar
• 49. Smith DM, Namvar T, Brown RP et al. Assessment of primary care practitioners' attitudes and interest in pharmacogenomic testing. Pharmacogenomics 21(15), 1085–1094 (2020).
  CASGoogle Scholar
• 50. Veilleux S, Bouffard M, Bourque Bouliane M. Patient and health care provider needs and preferences in understanding pharmacogenomic and genomic testing: a meta-data analysis. Qual. Health Res. 30(1), 43–59 (2020).
  MedlineGoogle Scholar
• 51. St. Sauver JL, Bielinski SJ, Olson JE et al. Integrating pharmacogenomics into clinical practice: promise vs reality. Am. J. Med. 129(10), 1093–1099.e1091 (2016).
  MedlineGoogle Scholar
• 52. Warning Letter, Inova Genomics Laboratory. US FDA, Silver Spring, MD, USA (2019).
  Google Scholar
• 53. Wilson PWF, Polonsky TS, Miedema MD, Khera A, Kosinski AS, Kuvin JT. Systematic review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 73(24), 3210–3227 (2019).
  MedlineGoogle Scholar
• 54. Grundy SM, Stone NJ, Bailey AL et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139(25), e1082–e1143 (2019).
  MedlineGoogle Scholar
• 55. FDA Drug Safety Communication: New Restrictions, Contraindications, and Dose Limitations for Zocor (Simvastatin) to Reduce the Risk of Muscle Injury. US FDA, Silver Spring, MD, USA (2017).
  Google Scholar